dc.creator | Papathanassiou M., Tamposis I., Exarchou-Kouveli K.K., Kontou P.I., de Paz A.T., Mitrakas L., Samara M., Bagos P.G., Tzortzis V., Vlachostergios P.J. | en |
dc.date.accessioned | 2023-01-31T09:44:44Z | |
dc.date.available | 2023-01-31T09:44:44Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.3389/fonc.2022.996553 | |
dc.identifier.issn | 2234943X | |
dc.identifier.uri | http://hdl.handle.net/11615/77849 | |
dc.description.abstract | Introduction: The use of immune checkpoint inhibitors (ICIs) as a front-line treatment for metastatic renal cell carcinoma (RCC) has significantly improved patient’ outcome. However, little is known about the efficacy or lack thereof of immunotherapy after prior use of anti-PD1/PD-L1 or/and anti-CTLA monoclonal antibodies. Methods: Electronic databases, including PubMed, EMBASE, Medline, Web of Science, and Cochrane Library, were comprehensively searched from inception to July 2022. Objective response rates (ORR), progression-free survival (PFS), and ≥ grade 3 adverse events (AEs) were assessed in the meta-analysis, along with corresponding 95% confidence intervals (CIs) and publication bias. Results: Ten studies which contained a total of 500 patients were included. The pooled ORR was 19% (95% CI: 10, 31), and PFS was 5.6 months (95% CI: 4.1, 7.8). There were ≥ grade 3 AEs noted in 25% of patients (95% CI: 14, 37). Conclusion: This meta-analysis on different second-line ICI-containing therapies in ICI-pretreated mRCC patients supports a modest efficacy and tolerable toxicity. Copyright © 2022 Papathanassiou, Tamposis, Exarchou-Kouveli, Kontou, de Paz, Mitrakas, Samara, Bagos, Tzortzis and Vlachostergios. | en |
dc.language.iso | en | en |
dc.source | Frontiers in Oncology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144216839&doi=10.3389%2ffonc.2022.996553&partnerID=40&md5=00a130de35a584c18ae7c4776a153a26 | |
dc.subject | atezolizumab | en |
dc.subject | axitinib | en |
dc.subject | bevacizumab | en |
dc.subject | durvalumab | en |
dc.subject | immune checkpoint inhibitor | en |
dc.subject | ipilimumab | en |
dc.subject | lenvatinib | en |
dc.subject | monoclonal antibody | en |
dc.subject | nivolumab | en |
dc.subject | pembrolizumab | en |
dc.subject | programmed death 1 ligand 1 | en |
dc.subject | programmed death 1 receptor | en |
dc.subject | temozolomide | en |
dc.subject | vasculotropin | en |
dc.subject | adverse drug reaction | en |
dc.subject | cancer patient | en |
dc.subject | cancer survival | en |
dc.subject | drug tolerability | en |
dc.subject | glioblastoma | en |
dc.subject | hospitalization | en |
dc.subject | human | en |
dc.subject | immunotherapy | en |
dc.subject | meta analysis | en |
dc.subject | overall response rate | en |
dc.subject | overall survival | en |
dc.subject | phase 3 clinical trial (topic) | en |
dc.subject | progression free survival | en |
dc.subject | randomized controlled trial (topic) | en |
dc.subject | renal cell carcinoma | en |
dc.subject | Review | en |
dc.subject | systematic review | en |
dc.subject | Frontiers Media S.A. | en |
dc.title | Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis | en |
dc.type | other | en |